Group 1 - The core viewpoint of the news is that Jitai Technology has completed a Series D financing round of 400 million RMB, which will accelerate the development of its Open CGT platform and other strategic initiatives [1][2] - The financing was led by the Beijing Pharmaceutical and Health Industry Investment Fund and the Daxing District Industrial Investment Fund, focusing on innovative drugs and medical devices [1] - The Open CGT platform aims to address industry pain points in precise drug delivery, reducing development barriers and costs, and fostering breakthrough CGT therapies [1][2] Group 2 - Jitai Technology's Open CGT platform will connect research capabilities from top universities, resources from major hospitals, and the full R&D chain of CGT innovative drug companies [2] - The platform has initiated its first project, empowering Ruizheng Gene to develop an mRNA-LNP-based liver-targeted CRISPR gene editing therapy [2] - The CEO of Jitai Technology emphasized that CGT will be a pillar of China's biopharmaceutical industry, representing the next generation of drug development through cellular and nucleic acid sequences [2]